YouScript, a clinical decision support tool designed to assist in medication therapy management, has been shown to reduce hospital readmissions by 52% and ER visits by 42% in patients over 50 taking multiple medications when combined with pharmacogenetic testing.Read More
Leerink resumed coverage of Invitae (NASDAQ:NVTA) with an “outperform” rating and $12 price target. The stock closed at $8.44 on Wednesday.
Analyst Puneet Souda writes that Invitae is a high growth, commercial-stage diagnostics company focused on building a business around genetic testing in a sizable and growing multibillion-dollar market.Read More
Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday.
“Our positive thesis contemplates a forward adjusted EBITDA (excluding non-controlling interest) growth rate of 13% (2015-2019 estimated CAGR) and is based on three growth pillars,” writes analyst Ana Gupte.Read More